Myeloproliferative Disorders
3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BiocorpSB939
Prevail TherapeuticsLY2784544
ExelixisXL019
Clinical Trials (3)
Total enrollment: 203 patients across 3 trials
Study of SB939 in Subjects With Myelofibrosis
Start: Nov 2010Est. completion: Nov 201223 patients
Phase 2Completed
A Study in Myeloproliferative Disorders
Start: Apr 2010Est. completion: Feb 201880 patients
Phase 1Completed
A Safety Study of XL019 in Adults With Myelofibrosis
Start: Aug 2007100 patients
Phase 1Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.